ANL 23.10 Decreased By ▼ -0.70 (-2.94%)
ASC 16.10 Decreased By ▼ -0.30 (-1.83%)
ASL 22.25 Decreased By ▼ -0.40 (-1.77%)
BOP 8.55 Increased By ▲ 0.17 (2.03%)
BYCO 8.96 Increased By ▲ 0.15 (1.7%)
FCCL 18.07 Decreased By ▼ -0.40 (-2.17%)
FFBL 24.45 Decreased By ▼ -0.15 (-0.61%)
FFL 17.90 Decreased By ▼ -0.15 (-0.83%)
FNEL 8.40 Decreased By ▼ -0.14 (-1.64%)
GGGL 22.09 Decreased By ▼ -0.21 (-0.94%)
GGL 43.18 Decreased By ▼ -0.77 (-1.75%)
HUMNL 7.02 Decreased By ▼ -0.15 (-2.09%)
JSCL 20.85 Decreased By ▼ -0.73 (-3.38%)
KAPCO 37.90 Decreased By ▼ -0.20 (-0.52%)
KEL 3.61 Increased By ▲ 0.01 (0.28%)
MDTL 3.00 Decreased By ▼ -0.07 (-2.28%)
MLCF 36.30 Decreased By ▼ -0.18 (-0.49%)
NETSOL 153.30 Decreased By ▼ -4.45 (-2.82%)
PACE 5.98 Decreased By ▼ -0.03 (-0.5%)
PAEL 31.20 Decreased By ▼ -0.45 (-1.42%)
PIBTL 9.36 Decreased By ▼ -0.11 (-1.16%)
POWER 7.90 Decreased By ▼ -0.14 (-1.74%)
PRL 20.85 Decreased By ▼ -0.13 (-0.62%)
PTC 10.40 Increased By ▲ 0.02 (0.19%)
SILK 1.67 Decreased By ▼ -0.02 (-1.18%)
SNGP 43.19 Decreased By ▼ -0.56 (-1.28%)
TELE 22.06 Decreased By ▼ -0.64 (-2.82%)
TRG 173.50 Decreased By ▼ -2.41 (-1.37%)
UNITY 36.20 Decreased By ▼ -0.77 (-2.08%)
WTL 3.25 Decreased By ▼ -0.08 (-2.4%)
BR100 4,979 Decreased By ▼ -47.44 (-0.94%)
BR30 24,460 Decreased By ▼ -312.8 (-1.26%)
KSE100 46,636 Decreased By ▼ -284.38 (-0.61%)
KSE30 18,480 Decreased By ▼ -177.85 (-0.95%)

Coronavirus
VERY HIGH Source: covid.gov.pk
Pakistan Deaths
27,135
6324hr
Pakistan Cases
1,221,261
2,51224hr
4.4% positivity
Sindh
449,349
Punjab
420,615
Balochistan
32,722
Islamabad
103,923
KPK
170,738
World

AstraZeneca vaccine less effective against S.African strain: study

  • It has so far vaccinated more than 11 million people using either the Pfizer/BioNTech or Oxford/AstraZeneca shots.
07 Feb 2021

LONDON: The Oxford/AstraZeneca vaccine fails to prevent mild and moderate cases of the South African coronavirus strain, researchers said Sunday.

The University of Witwatersrand, Johannesburg, which conducted the trial, said in a statement that the vaccine "provides minimal protection against mild-moderate Covid-19 infection" from the variant.

But in a full paper due to be published on Monday, AstraZeneca said that none of the 2,000 participants developed serious symptoms.

That could mean it will still have an effect on severe disease, although there is not yet enough data to make a definitive judgement.

The data, which has not yet undergone peer review, "appear to confirm the theoretical observation that mutations in the virus seen in South Africa will allow ongoing transmission of the virus in vaccinated populations," it said.

"Protection against moderate-severe disease, hospitalisation or death could not be assessed in this study as the target population were at low risk."

But the vaccine developers in Britain said informally the results offered some hope that the vaccine could prevent deaths from the variant.

"We may not be reducing the total number of cases but there is still protection against deaths, hospitalisations and severe disease," said Sarah Gilbert, who led the development of the vaccine with the Oxford Vaccine Group.

It could also be "some time" before they determine its effectiveness for older people in fighting the strain, which is a growing presence in Britain, she told BBC television.

"We might have to put it together from a number of studies," she said.

Researchers are currently working to update the vaccine, and "have a version with the South African spike sequence in the works" that they would "very much like" to be ready for the autumn, she added.

UK vaccines minister Nadhim Zahawi said the government's strategy to combat the spread of the strain was to continue with its mass vaccination programme "as rapidly as possible" as well as "hyper-local surge testing" where it is detected.

Britain is in the midst of a massive vaccination drive, which it sees as its way out of one of the worst outbreaks in the world that has seen more than 112,000 fatalities among those testing positive for the virus.

It has so far vaccinated more than 11 million people using either the Pfizer/BioNTech or Oxford/AstraZeneca shots.

The AstraZeneca vaccine has been the source of an ugly row with the European Union, which is angry that the Anglo-Swedish firm was unable to meet the delivery target agreed with Brussels.

France, Germany and Switzerland are also among countries to recommend the vaccine not be used for the elderly due to a lack of data.

Comments

Comments are closed.